Verve Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $857.05 million
- Book Value:
- Revenue TTM:
- $5.44 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Verve Therapeutics Inc had its IPO on 2021-06-17 under the ticker symbol VERV.
The company operates in the Healthcare sector and Biotechnology industry. Verve Therapeutics Inc has a staff strength of 204 employees.
Shares of Verve Therapeutics Inc opened at $13 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13 - $13.48, and closed at $13.36.
This is a +3.01% increase from the previous day's closing price.
A total volume of 345,322 shares were traded at the close of the day’s session.
In the last one week, shares of Verve Therapeutics Inc have slipped by -0.67%.
Verve Therapeutics Inc's Key Ratios
Verve Therapeutics Inc has a market cap of $857.05 million, indicating a price to book ratio of 2.542 and a price to sales ratio of 1294.4093.
In the last 12-months Verve Therapeutics Inc’s revenue was $5.44 million with a gross profit of $-128154000 and an EBITDA of $-204306000. The EBITDA ratio measures Verve Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Verve Therapeutics Inc’s operating margin was -3832.51% while its return on assets stood at -28.52% with a return of equity of -50.48%.
In Q2, Verve Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Verve Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.3 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Verve Therapeutics Inc’s profitability.
Verve Therapeutics Inc stock is trading at a EV to sales ratio of 992.5368 and a EV to EBITDA ratio of -6.2232. Its price to sales ratio in the trailing 12-months stood at 1294.4093.
Verve Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $589.13 million
- Total Liabilities
- $33.03 million
- Operating Cash Flow
- Capital Expenditure
- $2.66 million
- Dividend Payout Ratio
Verve Therapeutics Inc ended 2023 with $589.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $589.13 million while shareholder equity stood at $465.22 million.
Verve Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $33.03 million in other current liabilities, 62000.00 in common stock, $-450195000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $70.04 million and cash and short-term investments were $462.48 million. The company’s total short-term debt was $10,046,000 while long-term debt stood at $0.
Verve Therapeutics Inc’s total current assets stands at $473.07 million while long-term investments were $0 and short-term investments were $392.43 million. Its net receivables were $2.09 million compared to accounts payable of $3.15 million and inventory worth $0.
In 2023, Verve Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $2.66 million.
Comparatively, Verve Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Verve Therapeutics Inc stock is currently trading at $13.36 per share. It touched a 52-week high of $41.96 and a 52-week low of $41.96. Analysts tracking the stock have a 12-month average target price of $41.1.
Its 50-day moving average was $16.99 and 200-day moving average was $18.18 The short ratio stood at 19.88 indicating a short percent outstanding of 0%.
Around 1032.2% of the company’s stock are held by insiders while 10188.9% are held by institutions.
Frequently Asked Questions About Verve Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.